Market Overview

Recap: Rockwell Medical Q3 Earnings


Shares of Rockwell Medical (NASDAQ:RMTI) fell 2.17% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 16.67% over the past year to ($0.10), which were in line with the estimate of ($0.10).

Revenue of $15,280,000 declined by 0.82% year over year, which missed the estimate of $15,670,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Rockwell Medical hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

Time: 04:30 PM

ET Webcast URL:

Price Action

Company's 52-week high was at $3.85

Company's 52-week low was at $0.83

Price action over last quarter: down 48.85%

Company Description

Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The company's drug products are Triferic and Calcitriol. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Calcitriol is a generic drug for treating secondary hyperparathyroidism in dialysis patients. The company operates in one segment of the hemodialysis market which involves the manufacture, sale, and distribution of hemodialysis products. The majority of the revenue is generated form the United States.


Related Articles (RMTI)

View Comments and Join the Discussion!

Posted-In: Earnings